Latest Personalized medicine Stories
HARTFORD, Conn., March 4, 2013 /PRNewswire/ -- Genomas(®), a biomedical company delivering personalized medicine to modern clinical practice, has been awarded clinical laboratory licenses in three of the most populous States. The company's Laboratory of Personalized Health received licenses from the New York Department of Health, the Florida Agency for Health Care Administration, and the California Department of Public Health. Gualberto Ruano, M.D., Ph.D., President of Genomas and...
HAYWARD, Calif., March 4th, 2013 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) announced today that they have entered into an agreement with The Johns Hopkins University on behalf of its Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to use ACD's proprietary RNAscope® technology platform to validate novel biomarkers and drug targets for cancer immunotherapy. Cancer immunotherapy, which aims to mobilize a patient's immune system to fight cancer, has been gaining...
redOrbit Staff & Wire Reports - Your Universe Online An international team of researchers have produced what they are dubbing the “Google Maps” of human metabolism – the most comprehensive virtual recreation of the cellular chemical transformation ever crafted. The model is known as Recon 2, and according to the University of California, San Diego (UCSD) – one of the institutes behind the research – it could potentially be used to locate the causes of cancer, diabetes, and...
VALENCIA, Calif., Feb. 21, 2013 /PRNewswire/ -- SANGUINE BIOSCIENCES, INC. ("Sanguine"), a biotechnology company empowering patients in biomedical research, has announced the closing of its seed financing round, led by INVENT Ventures and Heliant Ventures. Sanguine engages research subjects through social media and non-profit advocacy, and schedules blood draws, which are then processed into DNA, RNA, cells, plasma, and serum, to be used as biomedical research materials at...
CARLSBAD, Calif., Feb. 21, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that the new Center for Personalized Medicine (CPM) at Roswell Park Cancer Institute (RPCI) has purchased four Ion Proton(TM) sequencers and two Ion Personal Genome Machine(TM) (PGM(TM)) sequencers. Founded in 1898, Roswell Park Cancer Institute was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and...
SUNNYVALE, Calif., Feb. 19, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) and the Knight Cancer Institute at Oregon Health & Science University (OHSU) today announced a collaboration to develop a menu of advanced molecular diagnostics to be performed on the GeneXpert system. The collaboration will focus on the development of clinical oncology tests for the GeneXpert system and will establish a system for clinically validating the tests through the Knight Diagnostic...
Genetic medicine experts from Manchester Biomedical Research Centre at Saint Mary's Hospital and The University of Manchester have identified a new gene responsible for causing an inherited form of tumor, known as spinal meningioma. Professor Richard Marias, Director of the Paterson Institute Meningiomas are the commonest form of tumor affecting the brain and spine. Usually meningiomas can be removed by surgery and do not recur. Occasionally people can develop more than one meningioma or...
MONTREAL, Feb. 15, 2013 /PRNewswire/ - The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC). This public-private partnership will be focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec and...
GERMANTOWN, Maryland and HILDEN, Germany, February 13, 2013 /PRNewswire/ -- - Arrangement to facilitate future collaborations in personalized medicine - Provides framework to develop and commercialize QIAGEN companion diagnostics paired with Lilly medicines in an effort to improve outcomes for individual patients - Builds on the two companies' recent mutual successes QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today...
BETHLEHEM, Pa., Feb. 11, 2013 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine, announced today that the My5-FU(TM) Assay will be part of the Saladax Biomedical Laboratories MyCare(TM) service offering when the CLIA laboratory located in Bethlehem, PA commences operations later this year. My5-FU is a simple blood test that provides oncologists with objective...
